carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['duo-o', 'gyn', 'bevacizumab', 'brca']
an interim pfs analysis of the ongoing phase 3 duo-o trial found that in a non brca-mutant hrd+ tumor population, the median pfs was 37.3 months in the maintenance triplet arm vs 23.0 months in the maintenance bevacizumab alone arm. #gyncsm #asco23 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.